Pricing Reports

NICE INSIGHT REPORT

Antibody–Drug Conjugate, ADC: Market Insight, CDMO Pricing and Competitor Benchmarking

Updated Monthly
  • 2025 CDMO pricing data for 45 clinical and commercial ADC development and manufacturing RFP service line items
  • Region-based pricing breakdown across North America, Europe, and APAC
  • Exhaustive directory of capabilities profiles for the top 44 biologics CDMOs specializing in ADC development
  • Technical focus on linker technologies and antibody conjugation techniques
  • Includes Nice Insight’s Clinical Trials Landscape tool — an in-depth custom research platform for current and upcoming ADC trials, sourced from the FDA Clinical Trials Database
Learn More
Antibody–Drug Conjugate, ADC

Key market insights for innovators, CDMOs and investors in the Antibody–Drug Conjugate industry.

Request a Sample

The market trends that decision makers need to know

Our complete Market Analysis uses scientific insights from PhDs and researchers to provide an exhaustive overview of the ADC industry. From the emergence of ADCs as cancer treatments to how big pharma has penetrated ADC, stay ahead of market trends with our report.

 

Exclusive pricing data to benchmark against peers

Keep your sales team ahead of the curve by using our primary data for an accurate pricing comparison. Our Market Analysis provides a manufacturing process and strategic pricing study designed to give CDMOs a competitive edge.

You Might Be Interested In

Active Pharmaceutical Ingredients, API

Active Pharmaceutical Ingredients, API: Market Insight, CDMO Pricing and Competitor Benchmarking

Updated Monthly

LEARN MORE
Mammalian Cell Culture, Biologics

Mammalian Cell Culture, Biologics: Market Insight, CDMO Pricing and Competitor Benchmarking

Updated Monthly

LEARN MORE
Update cookies preferences